SCHEMBL4411336

SCHEMBL4411336

CCOc1cc(O)c(F)c(N2Cc3cnc(NC4CCC(O)CC4)nc3N(CC)C2=O)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR4 P22455 11/20 0.41
MAPK14 Q16539 2/20 0.40
TNK2 Q07912 3/20 0.38
MAP4K2 Q12851 3/20 0.38
FGFR1 P11362 3/20 0.36
EGFR P00533 3/20 0.36
FYN P06241 2/20 0.36
PDGFRB P09619 2/20 0.36
PDGFRA P16234 2/20 0.36
FGFR2 P21802 2/20 0.36
FGFR3 P22607 2/20 0.36
MAPK1 P28482 2/20 0.36
KDR P35968 2/20 0.36
EPHB3 P54753 2/20 0.36
PRKACA P17612 1/20 0.36
PRKACG P22612 1/20 0.36
PRKACB P22694 1/20 0.36
MAPK8 P45983 1/20 0.34
MAPK9 P45984 1/20 0.34
MAPK10 P53779 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4404746 0.94 FGFR4 (0.47) FGFR4MAPK14TNK2MAP4K2FGFR1
SCHEMBL4395956 0.93 FGFR4 (0.40) FGFR4TNK2MAP4K2FGFR1EGFR
SCHEMBL4403342 0.92 FGFR4 (0.40) FGFR4TNK2MAP4K2FGFR1EGFR
SCHEMBL4411766 0.91 FGFR4 (0.47) FGFR4MAPK14FGFR1EGFRFYN
SCHEMBL4402988 0.90 EGFR (0.45) FGFR4MAPK14FGFR1EGFRFYN
SCHEMBL4411825 0.88 FGFR4 (0.42) FGFR4TNK2MAP4K2FGFR1EGFR
SCHEMBL4398479 0.87 FGFR4 (0.46) FGFR4TNK2MAP4K2FGFR1EGFR
SCHEMBL4410526 0.86 FGFR4 (0.47) FGFR4MAPK14FGFR1FGFR2FGFR3
SCHEMBL4403030 0.86 FGFR4 (0.52) FGFR4MAPK14FGFR1EGFRFYN
SCHEMBL4406590 0.85 FGFR4 (0.45) FGFR4TNK2MAP4K2FGFR1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1549651-B1 PYRIMIDOPYRIMIDONES AS KINASE INHIBITORS WARNER LAMBERT CO (US) 2009-12-23 EP disclosed
US-7196090-B2 Kinase inhibitors WARNER-LAMBERT COMPANY (US) 2007-03-27 US disclosed
WO-2006038112-A1 USE OF KINASE INHIBITORS TO PROMOTE NEOCHONDROGENESIS WARNER-LAMBERT COMPANY LLC (US) 2006-04-13 WO disclosed
EP-1549651-A1 KINASE INHIBITORS Warner-Lambert Company LLC (US) 2005-07-06 EP disclosed
WO-2004011465-A1 KINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-05 WO disclosed
US-20040019210-A1 Kinase inhibitors CHIVIKAS CONNOLLY CLEO J (US) 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019210-A1 Kinase inhibitors CDK2, CDK1, CDK4 FGFR4 191/4885MAPK14 229/4885TNK2 140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.